than high-dose hydrochlorothiazide (50 mg or more) and beta-blockers. A 2019 review supported equivalence between drug classes for initiating monotherapy in hypertension, although thiazide or thiazide-like diuretics showed better primary effectiveness and safety profiles than angiotensin-converting enzyme inhibitors and non-dihydropyridine calcium channel blockers.

The use of low-dose thiazide diuretics, including other thiazide diuretics equivalent to less than 50mg of hydrochlorothiazide, together with other antihypertensive drug